Contact
searchSearch
HMP Global
Login

B-Cell Lymphoma Resource Center

Conference Coverage
Improving Outcomes in Diffuse Large B-Cell Lymphoma: Molecular Subtypes and Early Response Assessments
12/15/2025
Grace Taylor, MS, MA
A presentation at ASH 2025 explored recent treatment options for diffuse large B-cell lymphoma (DLBCL), highlighting the targeting of molecular subtypes using genomic profiling, monitoring techniques including PET and evaluation of minimal...
A presentation at ASH 2025 explored recent treatment options for diffuse large B-cell lymphoma (DLBCL), highlighting the targeting of molecular subtypes using genomic profiling, monitoring techniques including PET and evaluation of minimal...
A presentation at ASH 2025...
12/15/2025
Journal of Clinical Pathways
Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
R-CHOP Followed by R-ICE Regimen vs Standard-of-Care Therapy for Patients With Non-GCB DLBCL
03/12/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD ...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses...
03/12/2024
Oncology
From Oncology
News
Real-World Clinical Effectiveness of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-cell Lymphoma
01/30/2024
Grace Taylor, MS, MA
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L. Crombie, MD, and...
01/30/2024
Journal of Clinical Pathways
Conference Coverage
Incidence and Survival Outcomes of Diffuse Large B-Cell Lymphoma in Adolescents and Young Adults
12/07/2023
Grace Taylor, MS, MA
A team of researchers conducted a study to determine the influence of race on the occurrence and survival outcomes of DLBCL among adolescents and young adults.
A team of researchers conducted a study to determine the influence of race on the occurrence and survival outcomes of DLBCL among adolescents and young adults.
A team of researchers conducted...
12/07/2023
Journal of Clinical Pathways
News
Cost-Effectiveness of Lisocabtagene Maraleucel vs Axicabtagene Ciloleucel and Tisagenlecleucel for Third-Line or Later Treatment for R/R DLBCL
09/12/2023
Grace Taylor, MS, MA
Researchers compared the cost of treatment for different chimeric antigen receptor T-cell therapies as third-line or later treatment for patients with relapsed or refractory large B-cell lymphoma in the US.
Researchers compared the cost of treatment for different chimeric antigen receptor T-cell therapies as third-line or later treatment for patients with relapsed or refractory large B-cell lymphoma in the US.
Researchers compared the cost of...
09/12/2023
Journal of Clinical Pathways
Stephen Edge, MD.
Videos
Clinical Pathways in Practice at Roswell Park Cancer Center
09/05/2023
Stephen Edge, MD
Stephen Edge, MD, vice president for system quality and outcomes at the Roswell Park Comprehensive Cancer Center and the University of Buffalo in Buffalo, New York, spoke with the Journal of Clinical Pathways about his experience using...
Stephen Edge, MD, vice president for system quality and outcomes at the Roswell Park Comprehensive Cancer Center and the University of Buffalo in Buffalo, New York, spoke with the Journal of Clinical Pathways about his experience using...
Stephen Edge, MD, vice president...
09/05/2023
Journal of Clinical Pathways
News
NCCN Updates Clinical Practice Guidelines for B-Cell Lymphomas
08/30/2023
Grace Taylor, MS, MA
NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.
NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.
NCCN recently published updated...
08/30/2023
Journal of Clinical Pathways
News
The Impact of Demographic Factors on Time to Diagnosis for Patients With Diffuse Large B-Cell Lymphoma
08/03/2023
Grace Taylor, MS, MA
Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).
Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).
Researchers investigated how...
08/03/2023
Journal of Clinical Pathways
Manali Kamdar Headshot
Videos
Overview of Treatment Options for Patients With Primary Refractory/Early Relapse Diffuse Large B-Cell Lymphoma
07/19/2023
Manali Kamdar, MD
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of...
07/19/2023
Journal of Clinical Pathways
News
Analysis of Racial Disparities in Cancer-Specific Survival Rates of Patients with Diffuse Large B-Cell Lymphoma
07/06/2023
Grace Taylor, MS, MA
In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.
In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.
In a recent study, Soyon Lee,...
07/06/2023
Journal of Clinical Pathways
Conference Coverage
Overall Survival Analysis of Patients with R/R LBCL Receiving Axicabtagene Ciloleucel vs Standard of Care Therapy: ZUMA-7 Study
06/27/2023
Grace Taylor, MS, MA
Jason Westin, MD, and colleagues examined the overall survival of patients with R/R LBCL who received axicabtagene ciloleucel vs standard of care for second-line therapy as part of the ZUMA-7 clinical trial.
Jason Westin, MD, and colleagues examined the overall survival of patients with R/R LBCL who received axicabtagene ciloleucel vs standard of care for second-line therapy as part of the ZUMA-7 clinical trial.
Jason Westin, MD, and colleagues...
06/27/2023
Journal of Clinical Pathways

Expert Insights

Andrew Zelenetz, MD, Memorial Sloan Kettering Cancer Center
Videos
R-CHOP Followed by R-ICE Regimen vs Standard-of-Care Therapy for Patients With Non-GCB DLBCL
03/12/2024

Featuring Andrew Zelenetz, MD

Featuring Andrew Zelenetz, MD ...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses next steps for evaluating long-term data on potential improved outcomes from R-CHOP induction preceding R-ICE consolidation vs standard-of-care therapy among patients with non-germinal center B-cell-like diffuse...
Andrew Zelenetz, MD, discusses...
03/12/2024
Oncology
Stephen Edge, MD.
Videos
Clinical Pathways in Practice at Roswell Park Cancer Center
09/05/2023
Stephen Edge, MD
Stephen Edge, MD, vice president for system quality and outcomes at the Roswell Park Comprehensive Cancer Center and the University of Buffalo in Buffalo, New York, spoke with the Journal of Clinical Pathways about his experience using...
Stephen Edge, MD, vice president for system quality and outcomes at the Roswell Park Comprehensive Cancer Center and the University of Buffalo in Buffalo, New York, spoke with the Journal of Clinical Pathways about his experience using...
Stephen Edge, MD, vice president...
09/05/2023
Journal of Clinical Pathways
Manali Kamdar Headshot
Videos
Overview of Treatment Options for Patients With Primary Refractory/Early Relapse Diffuse Large B-Cell Lymphoma
07/19/2023
Manali Kamdar, MD
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of Colorado Cancer Center, discusses the latest therapeutic options available for patients with primary refractory/early relapse diffuse large B-cell lymphoma.
Manali Kamdar, MD, University of...
07/19/2023
Journal of Clinical Pathways
Kathryn Tringale, MD, MAS
Videos
The Benefits of Incorporating Radiation Therapy Into the Treatment of Primary CNS Lymphoma
01/05/2023
At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...
At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...
At the 64th ASH Annual Meeting,...
01/05/2023
Journal of Clinical Pathways
Kathryn Tringale, MD, MAS
Videos
Retrospective Analysis of Survival Outcomes Following Treatment for Primary CNS Lymphoma
01/05/2023
Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...
Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...
Kathryn Tringale, MD, MAS,...
01/05/2023
Journal of Clinical Pathways
Matthew Maurer, DSc
Videos
Developing a Prognostic Model for Patients With Follicular Lymphoma
12/14/2022
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting,...
12/14/2022
Journal of Clinical Pathways
Alice J Chen, PhD
Videos
The Value of Reducing CAR-T Treatment Wait Times Among Patients With Diffuse Large B-cell Lymphoma
10/04/2022
Alice J Chen, PhD, found that delays affected access to CAR-T treatments and treatment effectiveness among patients with refractory and relapsed aggressive blood cancer.
Alice J Chen, PhD, found that delays affected access to CAR-T treatments and treatment effectiveness among patients with refractory and relapsed aggressive blood cancer.
Alice J Chen, PhD, found that...
10/04/2022
Journal of Clinical Pathways
Patrick Bliven, MD
Videos
Patterns of Therapy Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
08/03/2022
Patrick Bliven, MD, discusses report patterns and therapy utilization in patients with relapsed/refractory diffuse large B-cell lymphoma, comparing overall survival among double-hit lymphoma (DHL) and non-DHL subgroups for chimeric antigen...
Patrick Bliven, MD, discusses report patterns and therapy utilization in patients with relapsed/refractory diffuse large B-cell lymphoma, comparing overall survival among double-hit lymphoma (DHL) and non-DHL subgroups for chimeric antigen...
Patrick Bliven, MD, discusses...
08/03/2022
Journal of Clinical Pathways
Peter Riedell, MD
Videos
Real-World Safety, Efficacy, and Utilization of Axicabtagene Ciloleucel and Tisagenlecleucel for B-Cell Lymphomas
01/21/2022
Peter Riedell, MD, discusses findings from a study that assessed safety, patterns of use, resource utilization, and efficacy with commercial axicabtagene ciloleucel and tisagenlecleucel for the treatment of relapsed/refractory B-cell...
Peter Riedell, MD, discusses findings from a study that assessed safety, patterns of use, resource utilization, and efficacy with commercial axicabtagene ciloleucel and tisagenlecleucel for the treatment of relapsed/refractory B-cell...
Peter Riedell, MD, discusses...
01/21/2022
Journal of Clinical Pathways
Patrick Connor Johnson, MD
Videos
Physician Survey Reveals Key Attributes for Third-Line Treatment Selection for DLBCL
10/18/2021
Patrick Connor Johnson, MD, discusses study results on physician perspectives regarding key attributes for selecting third-line treatment for DLBCL.
Patrick Connor Johnson, MD, discusses study results on physician perspectives regarding key attributes for selecting third-line treatment for DLBCL.
Patrick Connor Johnson, MD,...
10/18/2021
Journal of Clinical Pathways
Quality Outlook
Measuring Justice in Breast Cancer Screening: A Bioethical Framework for Analyzing Quality Measures
03/10/2026
Nandita Ammanamanchi, BA; Rachel Delinger, MPH; David Blaisdell, BA; Tom Valuck, MD, JD
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality Outlook blog series applies a bioethical justice framework to evaluate breast cancer screening quality measures, highlighting how equity-oriented analysis can uncover access disparities, inform measure refinement,...
This entry of the Quality...
03/10/2026
Journal of Clinical Pathways
Ovarian cancer, Rosella trial
Videos
Advancing Treatment in Platinum-Resistant Ovarian Cancer: Clinical Impact of the ROSELLA Trial
03/03/2026
Robert L. Colemen, MD, FACOG, FACS
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses how the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel significantly improved overall survival in patients with platinum-resistant ovarian cancer.
Robert Coleman, MD, discusses...
03/03/2026
Journal of Clinical Pathways
Non-small cell lung cancer, NSCLC
Videos
Examining Equity Gaps in Immune Checkpoint Inhibitor Trials for NSCLC
02/25/2026
Adam Barsouk, MD
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses how underrepresentation in NSCLC immunotherapy trials continues to influence survival outcomes and what must change to achieve more equitable care.
Adam A. Barsouk, MD, discusses...
02/25/2026
Journal of Clinical Pathways
Quality Outlook
The Rising and Setting of Health Equity
02/24/2026
David Sloan, PhD; Tom Valuck, MD, JD
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating health equity into value-based care, recent federal policy changes are reshaping how disparities are measured, reported, and addressed across the US health system.
After years of integrating...
02/24/2026
Journal of Clinical Pathways
JJN
Interview
NSCLC Clinical Pathways in the Era of Molecular Complexity, AI, and Value-Based Care
02/20/2026
Jorge J. Nieva, MD
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest expert discusses how clinical pathways in EGFR- and ALK-mutated non-small cell lung cancer (NSCLC) must adapt to growing molecular complexity, integrate emerging technologies such as artificial intelligence and...
In this interview, a guest...
02/20/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Interview
Reflex NGS and PD-L1 Testing Streamlines Biomarker Turnaround and Treatment Planning in Resectable NSCLC
01/27/2026
Tina Edmonston, MD; David D. Shersher, MD
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David...
01/27/2026
Journal of Clinical Pathways
Woyach Headshot
Interview
Targeting BTK Mutations in CLL: Emerging Data on Rocbrutinib
12/18/2025
Jennifer Ann Woyach, MD
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early...
12/18/2025
Journal of Clinical Pathways
Joanna Rhodes, MD, MSCE
Interview
Transforming CLL Management: How MRD Could Shape Treatment Duration and Decision-Making
12/17/2025
Joanna M. Rhodes, MD, MSCE
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion,...
12/17/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Medicare and Cancer Care Reform: Closing the Gaps in Access and Affordability
12/15/2025
Youngmin Kwon
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral...
12/15/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice: Part 2
12/04/2025
Houda Hachad, PharmD
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses...
12/04/2025
Journal of Clinical Pathways

Newsfeed

News
Real-World Clinical Effectiveness of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-cell Lymphoma
01/30/2024
Grace Taylor, MS, MA
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L. Crombie, MD, and...
01/30/2024
Journal of Clinical Pathways
News
Cost-Effectiveness of Lisocabtagene Maraleucel vs Axicabtagene Ciloleucel and Tisagenlecleucel for Third-Line or Later Treatment for R/R DLBCL
09/12/2023
Grace Taylor, MS, MA
Researchers compared the cost of treatment for different chimeric antigen receptor T-cell therapies as third-line or later treatment for patients with relapsed or refractory large B-cell lymphoma in the US.
Researchers compared the cost of treatment for different chimeric antigen receptor T-cell therapies as third-line or later treatment for patients with relapsed or refractory large B-cell lymphoma in the US.
Researchers compared the cost of...
09/12/2023
Journal of Clinical Pathways
News
NCCN Updates Clinical Practice Guidelines for B-Cell Lymphomas
08/30/2023
Grace Taylor, MS, MA
NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.
NCCN recently published updated recommendations for the treatment of diffuse large B-cell lymphoma (DLBCL) and histologic transformation of indolent lymphomas to DLBCL.
NCCN recently published updated...
08/30/2023
Journal of Clinical Pathways
News
The Impact of Demographic Factors on Time to Diagnosis for Patients With Diffuse Large B-Cell Lymphoma
08/03/2023
Grace Taylor, MS, MA
Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).
Researchers investigated how socioeconomic status, race, and primary language spoken at home can affect time to diagnosis for patients with diffuse large B-cell lymphoma (DLBCL).
Researchers investigated how...
08/03/2023
Journal of Clinical Pathways
News
Analysis of Racial Disparities in Cancer-Specific Survival Rates of Patients with Diffuse Large B-Cell Lymphoma
07/06/2023
Grace Taylor, MS, MA
In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.
In a recent study, Soyon Lee, MPH, and John D. Seeger, PhD, Harvard T.H. Chan School of Public Health, Boston, MA, examined the association between race and cancer-specific survival among patients with diffuse large B-cell lymphoma.
In a recent study, Soyon Lee,...
07/06/2023
Journal of Clinical Pathways
News
Geographic Barriers Limit CAR T-Cell Therapy Access in US Medicare Patients With DLBCL
03/12/2026
Grace Taylor, MS, MA
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in Blood Advances reveals that geographic distance and socioeconomic status significantly shape CAR T access and survival outcomes for US patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
A SEER-Medicare analysis in...
03/12/2026
Journal of Clinical Pathways
News
Social Drivers Linked to Hepatocellular Carcinoma Stage and Survival in US Integrated Care System
03/09/2026
Hannah Musick
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health system, Asian and Pacific Islander patients with hepatocellular carcinoma (HCC) had lower odds of advanced-stage diagnosis and better 5-year survival, while residence in socioeconomically deprived neighborhoods...
In a large integrated US health...
03/09/2026
Journal of Clinical Pathways
News
FDA Approves Pembrolizumab Plus Paclitaxel for Platinum-Resistant Ovarian Cancer in the US
03/06/2026
Hannah Musick
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug Administration (FDA) has approved pembrolizumab in combination with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma, based on improved...
The US Food and Drug...
03/06/2026
Journal of Clinical Pathways
News
Real-World Data Support Earlier T-DXd Use in HR+/HER2-Low Metastatic Breast Cancer
03/04/2026
Grace Taylor, MS, MA
Earlier use of trastuzumab deruxtecan (T-DXd) in hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer was associated with longer real-world treatment duration and delayed need for...
Earlier use of trastuzumab deruxtecan (T-DXd) in hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer was associated with longer real-world treatment duration and delayed need for...
Earlier use of trastuzumab...
03/04/2026
Journal of Clinical Pathways
News
Neighborhood Socioeconomic Status Tied to Survival in US Early-Onset Metastatic Colorectal Cancer
02/19/2026
Hannah Musick
In a US community-based cohort of young adults with metastatic colorectal cancer, lower neighborhood socioeconomic status was independently associated with significantly higher mortality, highlighting the impact of structural disadvantage on...
In a US community-based cohort of young adults with metastatic colorectal cancer, lower neighborhood socioeconomic status was independently associated with significantly higher mortality, highlighting the impact of structural disadvantage on...
In a US community-based cohort...
02/19/2026
Journal of Clinical Pathways
News
Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in Metastatic TNBC
02/13/2026
Grace Taylor, MS, MA
In the phase 3 ASCENT-04/KEYNOTE-D19 trial, first-line sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival (PFS) and response durability compared with chemotherapy plus pembrolizumab in programmed...
In the phase 3 ASCENT-04/KEYNOTE-D19 trial, first-line sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival (PFS) and response durability compared with chemotherapy plus pembrolizumab in programmed...
In the phase 3...
02/13/2026
Journal of Clinical Pathways
News
Mobile App Self-Acupressure Reduces Ovarian Cancer Fatigue, Study Finds
02/13/2026
Grace Taylor, MS, MA
A mobile app–guided self-acupressure program significantly reduced cancer-related fatigue in women with ovarian cancer, with benefits sustained for up to 24 weeks.
A mobile app–guided self-acupressure program significantly reduced cancer-related fatigue in women with ovarian cancer, with benefits sustained for up to 24 weeks.
A mobile app–guided...
02/13/2026
Journal of Clinical Pathways
News
Interlocking Poverty, Stigma, and Information Gaps Drive Hospice Exclusion for Low-Income Cancer Patients
02/13/2026
Lisa Kuhns, PhD, MD
Hospice exclusion among low-income cancer patients is not the result of a single barrier but a reinforcing web of poverty, stigma, and unequal access to knowledge that systematically limits end-of-life care choices, according to study results...
Hospice exclusion among low-income cancer patients is not the result of a single barrier but a reinforcing web of poverty, stigma, and unequal access to knowledge that systematically limits end-of-life care choices, according to study results...
Hospice exclusion among...
02/13/2026
Journal of Clinical Pathways
News
Patient Navigation Improves Colorectal Cancer Screening in Washington, DC Safety Net
02/11/2026
Hannah Musick
A evaluation at a Washington, DC safety net health system found that patient navigation improved colorectal cancer screening and follow-up completion at a moderate per-patient cost.
A evaluation at a Washington, DC safety net health system found that patient navigation improved colorectal cancer screening and follow-up completion at a moderate per-patient cost.
A evaluation at a Washington, DC...
02/11/2026
Journal of Clinical Pathways
News
Tumor-Informed ctDNA Surveillance for HCC and CCA After Liver Transplant Shows High Specificity
02/09/2026
Grace Taylor, MS, MA
Personalized tumor-informed circulating tumor DNA (ctDNA) testing after liver transplantation shows high specificity but limited sensitivity for detecting recurrence in patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma...
Personalized tumor-informed circulating tumor DNA (ctDNA) testing after liver transplantation shows high specificity but limited sensitivity for detecting recurrence in patients with hepatocellular carcinoma (HCC) and cholangiocarcinoma...
Personalized tumor-informed...
02/09/2026
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: HCRU and Costs With CAR-T Therapy vs Transplantation for DLCBL
04/08/2021
04/08/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use